Table 1. Hematological variables measured at baseline (day 10) and after VEGF121 gene therapy (days 20 and 40).

Hematological variables

Control

pVEGF121

Physiological valuesa

day 10

day 20

day 40

day 10

day 20

day 40

Hemoglobin (g/L)

12.3±1.5

13.6±2.2

13.8±2.9

12.2±2.0

11.3±1.0

13.0±2.5

11.0-12.5

Hematocrit (%/vol)

40±5

44±7

45±5

37±4

38±3

41±2

38-40

Glycemia (mmol/L)

4.4±1.8

4.4±0.8

4.2±0.7

4.3±1.3

4.4±0.4

4.1±0.4

4-6

Creatinin (mmol/L)

74±14

82±16

96±6

72±7

89±11

93±8

50-100

Total proteins (g/L)

61.8±10.5

68.2±7.2

65.9±4.8

66.7±5.9

70.4±3.7

64.6±4.2

40-70

Albumin (g/L)

36.1±15.2

34.1±5.7

34.9±2.9

33.0±5.7

32.0±5.5

32.9±4.3

30-60

AP (U/L)

108±30

128±26

137±32

92±26

122±18

138±27

80-180

GPT (U/L)

25±11

27±4

31±10

17±3

27±10

34±5

2-40

GOT (U/L)

5.4±3.2

8.1±1.8

8.6±1.5

5.8±1.2

6.6±2.0

8.2±2.3

5-10

Coagulation time (min)

5.7±1.7

9.1±8.9

13.3±13.0

5.6±1.4

5.7±1.8

5.3±1.0

4-8

Bleeding time (min)

1.2±0.2

1.1±0.2

1.4±0.3

1.3±0.4

1.1±0.2

1.3±0.4

1-3

Platelet counting (x109)

163±41

198±41

194±40

199±41

193±47

185±54

130-200

a(Tvedten, 1981)
AP: alkaline phosphatase; GPT: glutamic-pyruvic transaminase; GOT: glutamic-oxaloacetic transaminase.


Supported by UNESCO / MIRCEN network